FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Multiple Myeloma

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Multiple Myeloma

November 6, 2025 Dr. Jennifer Chen Health

Here’s a breakdown of the provided text,extracting the cited ⁣sources:

  1. MedlinePlus:

⁣ * URL: https://medlineplus.gov/druginfo/meds/a620040.html#:~:text=Daratumumab%20and%20hyaluronidase%2Dfihj%20injection%20is%20used%20alone%20or%20in,Expand%20Section
* Accessed: ‍Not explicitly stated,but implied to be recent.

  1. CancerNetwork:

* Author: Conroy ⁣R.
* Title: FDA OKs subcutaneous ‌daratumumab in high-risk smoldering‌ multiple myeloma.
⁤ * Publication: CancerNetwork®
* Date: November 6, 2025.
⁣ * Accessed: November 6,2025.
⁢ * URL: ⁢https://www.cancernetwork.com/view/fda-oks-subcutaneous-daratumumab-in-high-risk-smoldering-multiple-myeloma